Welcome to our dedicated page for Telomir Pharms SEC filings (Ticker: TELO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, offering a structured view of how this preclinical-stage biotechnology company reports its progress and corporate events. Telomir’s filings show that it is a Florida corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol TELO, and they document its focus on developing Telomir-1, a small-molecule therapy targeting epigenetic and metabolic mechanisms in cancer and age-related disease.
For Telomir, Form 8‑K current reports are especially informative. Recent 8‑Ks include Item 8.01 disclosures of new preclinical data, such as Telomir-1’s effects on PSA levels in prostate cancer cells, tumor growth and metastasis in triple-negative breast cancer models, cytotoxicity in leukemia cells, and reductions in intracellular iron compared with the iron chelator Deferoxamine. Another 8‑K details completion of GLP toxicology and safety pharmacology studies in rat and dog models, noting that Telomir-1 was generally well tolerated with no treatment-related adverse or dose-limiting toxicities observed.
Filings also cover corporate and governance matters. Examples include an 8‑K describing a director resignation, compensation committee actions regarding the chief executive officer’s incentives, and a Nasdaq notice related to the timing of the company’s annual shareholder meeting under Listing Rule 5620(a). An additional 8‑K outlines a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc., intended to consolidate worldwide intellectual property and development rights to Telomir-1 within a single public company structure.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of GLP safety data, oncology study updates, compensation decisions, and Nasdaq communications. Users can review real-time updates from EDGAR, examine narrative descriptions of Telomir-1’s preclinical profile, and track how Telomir reports its IND-enabling activities and strategic transactions over time.